Invention Application
![SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR](/docs/US/2016-07-21/US20160207953A1/abs.jpg.600x600.jpg)
- Patent Title: SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR
-
Application No.: US15093178Application Date: 2016-04-07
-
Publication No.: US20160207953A1Publication Date: 2016-07-21
- Inventor: Spiros Liras , Vincent Mascitti , Benjamin Thuma
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Main IPC: C07H15/08
- IPC: C07H15/08 ; A61K31/7008 ; C07H15/26 ; A61K38/46 ; C07H15/12 ; A61K31/706 ; C07K5/065 ; C07H13/04 ; A61K31/7056
![SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR](/abs-image/US/2016/07/21/US20160207953A1/abs.jpg.150x150.jpg)
Abstract:
Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
Public/Granted literature
- US09617293B2 Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR Public/Granted day:2017-04-11
Information query
IPC分类:
